PHC Completes Supply Contract for COVID-19 Specimen Collection Kits in the US

[Asia Economy Reporter Jang Hyowon] PHC (CEO Choi Inhwan) announced on the 25th that it has completed the fulfillment of a supply contract worth approximately 6.2 billion KRW for COVID-19 specimen collection kits. The completed supply contracts have been exported to the United States since 2020 through H&Dream and CareCamp.

The supply contracts completed this time include a 3.2 billion KRW contract from September 2020 and a 2.9 billion KRW contract from January 2022. The increase in exports to the U.S. can be attributed to the spread of the Omicron variant and the rising demand for COVID-19 testing.

PHC recently obtained conditional domestic approval for its COVID-19 rapid antigen test kits and is aggressively expanding domestic sales. It is also in the process of obtaining domestic approval for saliva-based rapid antigen test kits, which have been recognized for excellent performance by the Australian TGA, indicating positive performance prospects for this year.

A company official stated, “With the global increase in demand for specimen collection kits due to the spread of the Omicron variant, we expect continuous follow-up supply contracts to be made.”

Meanwhile, PHC is steadily signing supply contracts for COVID-19 rapid diagnostic kits with several overseas countries and continues to export them consistently.

This content was produced with the assistance of AI translation services.